Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David M Jackman, M.D.

Title
Institution
Department
Address
Phone
Fax

Mentoring
Experience Implementing Oncology Clinical Pathways at an Academic Medical Center
Summer, 06/09/14 - 08/01/14

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Jackman DM, Hamilton J, Foster E, Bunnell CA, Culot L, Tremonti C, Jacobson JO. Lessons from the front: designing and implementing clinical pathways by and for clinicians. Am J Manag Care. 2020 02; 26(2 Spec No.):SP57-SP59. PMID: 32078281.
    Citations:    
  2. Sequist LV, Gray JE, Harb WA, Lopez-Chavez A, Doebele RC, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Adiwijaya B, Kuesters G, Kamoun WS, Andreas K, Pipas JM, Santillana S, Cho BC, Park K, Shepherd FA. Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. Oncologist. 2019 08; 24(8):1095-1102. PMID: 30975923.
    Citations:    
  3. Kadish SS, Mayer EL, Jackman DM, Pomerantz M, Brady L, Dimitriadis A, Cleveland JLF, Wagner AJ. Implementation to Optimization: A Tailored, Data-Driven Approach to Improve Provider Efficiency and Confidence in Use of the Electronic Medical Record. J Oncol Pract. 2018 07; 14(7):e421-e428. PMID: 29939808.
    Citations:    Fields:    
  4. Wood DE, Kazerooni EA, Baum SL, Eapen GA, Ettinger DS, Hou L, Jackman DM, Klippenstein D, Kumar R, Lackner RP, Leard LE, Lennes IT, Leung ANC, Makani SS, Massion PP, Mazzone P, Merritt RE, Meyers BF, Midthun DE, Pipavath S, Pratt C, Reddy C, Reid ME, Rotter AJ, Sachs PB, Schabath MB, Schiebler ML, Tong BC, Travis WD, Wei B, Yang SC, Gregory KM, Hughes M. Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Apr; 16(4):412-441. PMID: 29632061.
    Citations: 3     Fields:    
  5. Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, Powderly J, Heist R, Sequist LV, Smith DC, Leming P, Geese WJ, Yoon D, Li A, Brahmer J. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. J Clin Oncol. 2018 06 10; 36(17):1675-1684. PMID: 29570421.
    Citations: 9     Fields:    
  6. Jackman DM, Zhang Y, Dalby C, Nguyen T, Nagle J, Lydon CA, Rabin MS, McNiff KK, Fraile B, Jacobson JO. Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients With Stage IV Non-Small-Cell Lung Cancer. J Oncol Pract. 2017 04; 13(4):e346-e352. PMID: 28260402.
    Citations: 2     Fields:    Translation:Humans
  7. Agrawal V, Coroller TP, Hou Y, Lee SW, Romano JL, Baldini EH, Chen AB, Jackman DM, Kozono D, Swanson SJ, Wee JO, Aerts HJ, Mak RH. Radiologic-pathologic correlation of response to chemoradiation in resectable locally advanced NSCLC. Lung Cancer. 2016 12; 102:1-8. PMID: 27987576.
    Citations: 2     Fields:    Translation:Humans
  8. Redig AJ, Costa DB, Taibi M, Boucher D, Johnson BE, Jänne PA, Jackman DM. Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial. JAMA Oncol. 2016 Sep 01; 2(9):1240-2. PMID: 27387964.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  9. Yanagita M, Redig AJ, Paweletz CP, Dahlberg SE, O'Connell A, Feeney N, Taibi M, Boucher D, Oxnard GR, Johnson BE, Costa DB, Jackman DM, Jänne PA. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. Clin Cancer Res. 2016 Dec 15; 22(24):6010-6020. PMID: 27281561.
    Citations: 25     Fields:    Translation:HumansCellsCTClinical Trials
  10. Li R, Hermann G, Baldini E, Chen A, Jackman D, Kozono D, Nguyen P, Nohria A, Powell G, Mak R. Advanced nodal stage predicts venous thromboembolism in patients with locally advanced non-small cell lung cancer. Lung Cancer. 2016 06; 96:41-7. PMID: 27133748.
    Citations: 3     Fields:    Translation:Humans
  11. Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, Heng JC, Dahlberg SE, Jänne PA, Verma S, Christensen J, Hammerman PS, Sholl LM. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. J Clin Oncol. 2016 Mar 01; 34(7):721-30. PMID: 26729443.
    Citations: 55     Fields:    Translation:Humans
  12. Lin JJ, Cardarella S, Lydon CA, Dahlberg SE, Jackman DM, Jänne PA, Johnson BE. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol. 2016 Apr; 11(4):556-65. PMID: 26724471.
    Citations: 30     Fields:    Translation:Humans
  13. Calles A, Liao X, Sholl LM, Rodig SJ, Freeman GJ, Butaney M, Lydon C, Dahlberg SE, Hodi FS, Oxnard GR, Jackman DM, Jänne PA. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. J Thorac Oncol. 2015 Dec; 10(12):1726-35. PMID: 26473645.
    Citations: 29     Fields:    Translation:Humans
  14. Farago AF, Le LP, Zheng Z, Muzikansky A, Drilon A, Patel M, Bauer TM, Liu SV, Ou SH, Jackman D, Costa DB, Multani PS, Li GG, Hornby Z, Chow-Maneval E, Luo D, Lim JE, Iafrate AJ, Shaw AT. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol. 2015 Dec; 10(12):1670-4. PMID: 26565381.
    Citations: 31     Fields:    Translation:Humans
  15. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming P, Carbone DP, Pinder-Schenck MC, Topalian SL, Hodi FS, Sosman JA, Sznol M, McDermott DF, Pardoll DM, Sankar V, Ahlers CM, Salvati M, Wigginton JM, Hellmann MD, Kollia GD, Gupta AK, Brahmer JR. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2015 Jun 20; 33(18):2004-12. PMID: 25897158.
    Citations: 241     Fields:    Translation:HumansCTClinical Trials
  16. Lo PC, Dahlberg SE, Nishino M, Johnson BE, Sequist LV, Jackman DM, Jänne PA, Oxnard GR. Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. Cancer. 2015 Aug 01; 121(15):2570-7. PMID: 25876525.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  17. Calles A, Sholl LM, Rodig SJ, Pelton AK, Hornick JL, Butaney M, Lydon C, Dahlberg SE, Oxnard GR, Jackman DM, Jänne PA. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma. Clin Cancer Res. 2015 Jun 15; 21(12):2851-60. PMID: 25737507.
    Citations: 17     Fields:    Translation:HumansCells
  18. Jackman DM, Cioffredi LA, Jacobs L, Sharmeen F, Morse LK, Lucca J, Plotkin SR, Marcoux PJ, Rabin MS, Lynch TJ, Johnson BE, Kesari S. A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. Oncotarget. 2015 Feb 28; 6(6):4527-36. PMID: 25784657.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  19. Nishino M, Cardarella S, Dahlberg SE, Araki T, Lydon C, Jackman DM, Rabin MS, Hatabu H, Johnson BE. Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival. Eur J Radiol. 2015 May; 84(5):998-1004. PMID: 25726730.
    Citations: 8     Fields:    Translation:Humans
  20. Wood DE, Kazerooni E, Baum SL, Dransfield MT, Eapen GA, Ettinger DS, Hou L, Jackman DM, Klippenstein D, Kumar R, Lackner RP, Leard LE, Leung AN, Makani SS, Massion PP, Meyers BF, Otterson GA, Peairs K, Pipavath S, Pratt-Pozo C, Reddy C, Reid ME, Rotter AJ, Sachs PB, Schabath MB, Sequist LV, Tong BC, Travis WD, Yang SC, Gregory KM, Hughes M. Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2015 Jan; 13(1):23-34; quiz 34. PMID: 25583767.
    Citations: 26     Fields:    Translation:Humans
  21. Porter JM, Barysauskas C, Mach SL, Rodgers E, Elfiky A, Jacobson JO, Jackman DM. Development and implementation of clinical pathways in lung cancer at an academic comprehensive cancer center. J Clin Oncol. 2014 Oct 20; 32(30_suppl):98. PMID: 28141390.
    Citations:    
  22. Gray PJ, Mak RH, Yeap BY, Cryer SK, Pinnell NE, Christianson LW, Sher DJ, Arvold ND, Baldini EH, Chen AB, Kozono DE, Swanson SJ, Jackman DM, Alexander BM. Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival. Lung Cancer. 2014 Aug; 85(2):239-44. PMID: 24974152.
    Citations: 15     Fields:    Translation:Humans
  23. Parikh RB, Cronin AM, Kozono DE, Oxnard GR, Mak RH, Jackman DM, Lo PC, Baldini EH, Johnson BE, Chen AB. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):880-7. PMID: 24867533.
    Citations: 14     Fields:    Translation:Humans
  24. Nishino M, Jackman DM, DiPiro PJ, Hatabu H, Jänne PA, Johnson BE. Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy. Clin Radiol. 2014 Aug; 69(8):841-8. PMID: 24857677.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  25. Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P, Jackman DM, Jänne PA. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. 2014 Mar 15; 20(6):1698-1705. PMID: 24429876.
    Citations: 169     Fields:    Translation:HumansCells
  26. Goldberg SB, Oxnard GR, Digumarthy S, Muzikansky A, Jackman DM, Lennes IT, Sequist LV. Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors. Oncologist. 2013; 18(11):1214-20. PMID: 24072220.
    Citations: 43     Fields:    Translation:Humans
  27. Nishino M, Dahlberg SE, Cardarella S, Jackman DM, Rabin MS, Ramaiya NH, Hatabu H, Jänne PA, Johnson BE. Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression. Cancer. 2013 Nov 01; 119(21):3761-8. PMID: 23922022.
    Citations: 12     Fields:    Translation:Humans
  28. Nishino M, Dahlberg SE, Cardarella S, Jackman DM, Rabin MS, Hatabu H, Jänne PA, Johnson BE. Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI. J Thorac Oncol. 2013 Aug; 8(8):1059-68. PMID: 23787800.
    Citations: 11     Fields:    Translation:Humans
  29. Nishino M, Cardarella S, Jackman DM, Ramaiya NH, Rabin MS, Hatabu H, Jänne PA, Johnson BE. RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0. AJR Am J Roentgenol. 2013 Jul; 201(1):W64-71. PMID: 23789698.
    Citations: 14     Fields:    Translation:Humans
  30. Oxnard GR, Lo PC, Nishino M, Dahlberg SE, Lindeman NI, Butaney M, Jackman DM, Johnson BE, Jänne PA. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013 Feb; 8(2):179-84. PMID: 23328547.
    Citations: 35     Fields:    Translation:HumansCells
  31. Gaughan EM, Cryer SK, Yeap BY, Jackman DM, Costa DB. Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations. Lung Cancer. 2013 Mar; 79(3):193-7. PMID: 23273562.
    Citations: 9     Fields:    Translation:Humans
  32. Nishino M, Cardarella S, Dahlberg SE, Jackman DM, Ramaiya NH, Hatabu H, Rabin MS, Jänne PA, Johnson BE. Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. Lung Cancer. 2013 Mar; 79(3):283-8. PMID: 23254265.
    Citations: 15     Fields:    Translation:HumansCTClinical Trials
  33. Cardarella S, Ortiz TM, Joshi VA, Butaney M, Jackman DM, Kwiatkowski DJ, Yeap BY, Jänne PA, Lindeman NI, Johnson BE. The introduction of systematic genomic testing for patients with non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(12):1767-1774. PMID: 23154547.
    Citations: 29     Fields:    Translation:Humans
  34. Evans AG, French CA, Cameron MJ, Fletcher CD, Jackman DM, Lathan CS, Sholl LM. Pathologic characteristics of NUT midline carcinoma arising in the mediastinum. Am J Surg Pathol. 2012 Aug; 36(8):1222-7. PMID: 22790861.
    Citations: 16     Fields:    Translation:Humans
  35. Nishino M, Cryer SK, Okajima Y, Sholl LM, Hatabu H, Rabin MS, Jackman DM, Johnson BE. Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab. Cancer Imaging. 2012 Jun 29; 12:225-35. PMID: 22743083.
    Citations: 15     Fields:    Translation:Humans
  36. Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2012 Aug 15; 18(16):4406-14. PMID: 22733536.
    Citations: 48     Fields:    Translation:Humans
  37. Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, Liu Y, Tupper T, Ouyang J, Li J, Gao P, Woo MS, Xu C, Yanagita M, Altabef A, Wang S, Lee C, Nakada Y, Peña CG, Sun Y, Franchetti Y, Yao C, Saur A, Cameron MD, Nishino M, Hayes DN, Wilkerson MD, Roberts PJ, Lee CB, Bardeesy N, Butaney M, Chirieac LR, Costa DB, Jackman D, Sharpless NE, Castrillon DH, Demetri GD, Jänne PA, Pandolfi PP, Cantley LC, Kung AL, Engelman JA, Wong KK. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature. 2012 Mar 18; 483(7391):613-7. PMID: 22425996.
    Citations: 153     Fields:    Translation:HumansAnimalsCells
  38. Wood DE, Eapen GA, Ettinger DS, Hou L, Jackman D, Kazerooni E, Klippenstein D, Lackner RP, Leard L, Leung AN, Massion PP, Meyers BF, Munden RF, Otterson GA, Peairs K, Pipavath S, Pratt-Pozo C, Reddy C, Reid ME, Rotter AJ, Schabath MB, Sequist LV, Tong BC, Travis WD, Unger M, Yang SC. Lung cancer screening. J Natl Compr Canc Netw. 2012 Feb; 10(2):240-65. PMID: 22308518.
    Citations: 50     Fields:    Translation:Humans
  39. Girard N, Sima CS, Jackman DM, Sequist LV, Chen H, Yang JC, Ji H, Waltman B, Rosell R, Taron M, Zakowski MF, Ladanyi M, Riely G, Pao W. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J. 2012 Feb; 39(2):366-72. PMID: 21778168.
    Citations: 28     Fields:    Translation:Humans
  40. Mak RH, Doran E, Muzikansky A, Kang J, Neal JW, Baldini EH, Choi NC, Willers H, Jackman DM, Sequist LV. Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC. Oncologist. 2011; 16(6):886-95. PMID: 21632451.
    Citations: 17     Fields:    Translation:Humans
  41. Ortiz TM, Joshi VA, Heon S, Butaney M, Chen L, Jackman DM, Kwiatkowski DJ, Lindeman NI, Janne PA, Johnson BE. The introduction of systematic genomic testing for patients with non-small cell lung cancer (NSCLC) at Dana-Farber Cancer Institute (DFCI). J Clin Oncol. 2011 May 20; 29(15_suppl):7517. PMID: 28023283.
    Citations:    
  42. Heon S, Yeap BY, Lindeman NI, Rabin MS, Jackman DM, Johnson BE. Rates of central nervous system (CNS) metastases in patients with advanced non-small cell lung cancer (NSCLC) and somatic EGFR mutations initially treated with gefitinib or erlotinib versus chemotherapy. J Clin Oncol. 2011 May 20; 29(15_suppl):7607. PMID: 28023332.
    Citations:    
  43. Sequist LV, Harb WA, Modiano M, Jackman DM, Wong K, Engelman JA, Nering R, Onsum M, Moyo VM. A phase I/II trial of MM-121 in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol. 2011 May 20; 29(15_suppl):TPS215. PMID: 28023478.
    Citations:    
  44. Nishino M, Jackman DM, Hatabu H, Jänne PA, Johnson BE, Van den Abbeele AD. Imaging of lung cancer in the era of molecular medicine. Acad Radiol. 2011 Apr; 18(4):424-36. PMID: 21277232.
    Citations: 13     Fields:    Translation:Humans
  45. Nishino M, Guo M, Jackman DM, DiPiro PJ, Yap JT, Ho TK, Hatabu H, Jänne PA, Van den Abbeele AD, Johnson BE. CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool. Acad Radiol. 2011 Jan; 18(1):54-62. PMID: 21036632.
    Citations: 27     Fields:    Translation:Humans
  46. Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2010 Dec 01; 16(23):5873-82. PMID: 21030498.
    Citations: 66     Fields:    Translation:Humans
  47. Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, Jänne PA, Johnson BE, Van den Abbeele AD. New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol. 2010 Sep; 195(3):W221-8. PMID: 20729419.
    Citations: 61     Fields:    Translation:HumansCTClinical Trials
  48. Sholl LM, Xiao Y, Joshi V, Yeap BY, Cioffredi LA, Jackman DM, Lee C, Jänne PA, Lindeman NI. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol. 2010 Jun; 133(6):922-34. PMID: 20472851.
    Citations: 30     Fields:    Translation:Humans
  49. Doran E, Jackman D. Fire without smoke: lung cancer in 'never-smokers'. Oncology (Williston Park). 2010 Jan; 24(1):40, 43. PMID: 20187320.
    Citations: 1     Fields:    Translation:Humans
  50. Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Jänne PA, Lynch T, Johnson BE, Miller VA. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010 Jan 10; 28(2):357-60. PMID: 19949011.
    Citations: 215     Fields:    Translation:Humans
  51. Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Jänne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 2009 Aug 15; 15(16):5267-73. PMID: 19671843.
    Citations: 138     Fields:    Translation:Humans
  52. Jackman DM, Cioffredi L, Lindeman NI, Morse LK, Lucca J, Weckstein D, Huberman MS, Lynch TJ, Johnson BE, Janne PA. Phase II trial of erlotinib in chemotherapy-naive women with advanced pulmonary adenocarcinoma. J Clin Oncol. 2009 May 20; 27(15_suppl):8065. PMID: 27962638.
    Citations:    
  53. Souza FF, Jagganathan J, Ramayia N, Johnston C, Jackman D, Abbeele AV, Ros PR. Recurrent malignant peritoneal mesothelioma: radiological manifestations. Abdom Imaging. 2010 Jun; 35(3):315-21. PMID: 19319590.
    Citations: 1     Fields:    Translation:Humans
  54. Cioffredi LA, Jänne PA, Jackman DM. Treatment of peritoneal mesothelioma in pediatric patients. Pediatr Blood Cancer. 2009 Jan; 52(1):127-9. PMID: 18819151.
    Citations: 1     Fields:    Translation:Humans
  55. Jackman DM. Current options for systemic therapy in mesothelioma. Semin Thorac Cardiovasc Surg. 2009; 21(2):154-8. PMID: 19822287.
    Citations: 5     Fields:    Translation:Humans
  56. Yonesaka K, Zejnullahu K, Lindeman N, Homes AJ, Jackman DM, Zhao F, Rogers AM, Johnson BE, Jänne PA. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res. 2008 Nov 01; 14(21):6963-73. PMID: 18980991.
    Citations: 53     Fields:    Translation:HumansCells
  57. Costa DB, Nguyen KS, Cho BC, Sequist LV, Jackman DM, Riely GJ, Yeap BY, Halmos B, Kim JH, Jänne PA, Huberman MS, Pao W, Tenen DG, Kobayashi S. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res. 2008 Nov 01; 14(21):7060-7. PMID: 18981003.
    Citations: 57     Fields:    Translation:Humans
  58. Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, Morse LK, Ostler PA, Johnson BE, Jänne PA. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008 Aug 15; 113(4):808-14. PMID: 18543326.
    Citations: 21     Fields:    Translation:HumansCTClinical Trials
  59. Cooley ME, Emmons KM, Li H, Harrington DP, Christiani DC, Jackman DM, Cohen T, Johnson BE. Smoking history, drug toxicity, and survival in non-small cell lung cancer (NSCLC) patients receiving epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) drugs. J Clin Oncol. 2008 May 20; 26(15_suppl):9570. PMID: 27948168.
    Citations:    
  60. Jackman DM, Sequist LV, Cioffredi L, Ruiz MG, Janne PA, Giaccone G, Miller VA, Johnson BE. Impact of EGFR and KRAS genotype on outcomes in a clinical trial registry of NSCLC patients initially treated with erlotinib or gefitinib. J Clin Oncol. 2008 May 20; 26(15_suppl):8035. PMID: 27949020.
    Citations:    
  61. Rabin MS, Cioffredi L, Yeap BY, Williams RA, Johnson BE, Jackman DM. Rates of central nervous system progression in non-small cell lung cancer patients treated with EGFR-TKI's vs. chemotherapy. J Clin Oncol. 2008 May 20; 26(15_suppl):8059. PMID: 27948907.
    Citations:    
  62. Johnson BE, Jackman D, Jänne PA. Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 2):s4628-31. PMID: 17671154.
    Citations: 16     Fields:    Translation:HumansAnimals
  63. Jackman DM, Jänne PA. Does erlotinib improve symptoms in patients with lung cancer? Nat Clin Pract Oncol. 2007 Mar; 4(3):146-7. PMID: 17262089.
    Citations:    Fields:    
  64. Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Jänne PA. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007 Mar 01; 25(7):760-6. PMID: 17228019.
    Citations: 101     Fields:    Translation:HumansCTClinical Trials
  65. Johnson BE, Jackman DM, Janne PA. Impact of EGFR mutations on treatment of non-small cell lung cancer. Cancer Chemother Pharmacol. 2006; 58(Suppl 1):5-9.
  66. Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, Bailey C, de Jong F, Jänne PA, Johnson BE. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol. 2006 Sep 20; 24(27):4517-20. PMID: 16983123.
    Citations: 77     Fields:    Translation:Humans
  67. Nakabayashi M, Xie W, Regan MM, Jackman DM, Kantoff PW, Oh WK. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. Cancer. 2006 Sep 01; 107(5):975-81. PMID: 16862573.
    Citations: 7     Fields:    Translation:Humans
  68. Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006 Jul 01; 12(13):3908-14. PMID: 16818686.
    Citations: 160     Fields:    Translation:Humans
  69. Nakabayashi M, Xie W, Regan MM, Jackman DM, Kantoff PW, Oh WK. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):4646. PMID: 27952436.
    Citations:    
  70. Jackman DM, Yeap B, Lucca J, Ostler PA, Morse LK, Fidias P, Lynch TJ, Temel J, Johnson BE, Janne PA. Phase II trial of erlotinib in elderly patients (age > 70) with previously untreated advanced non-small cell lung cancer (NSCLC): An analysis of quality of life and symptom response. J Clin Oncol. 2006 Jun 20; 24(18_suppl):7168. PMID: 27953799.
    Citations:    
  71. Jackman DM, Skarin AT. Bronchioloalveolar carcinoma. 2006.
  72. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet. 2005 Oct 15-21; 366(9494):1385-96. PMID: 16226617.
    Citations: 124     Fields:    Translation:Humans
  73. Jackman DM, Chirieac LR, Jänne PA. Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment. Semin Respir Crit Care Med. 2005 Jun; 26(3):342-52. PMID: 16052436.
    Citations: 4     Fields:    Translation:Humans
  74. Jackman D, Lucca J, Fidias P, Rabin MS, Lynch TJ, Ostler P, Skarin AT, Temel J, Johnson BE, Janne PA. Phase II study of the EGFR tyrosine kinase erlotinib in patients = 70 years of age with previously untreated advanced non-small cell lung carcinoma. J Clin Oncol. 2005 Jun; 23(16_suppl):7148. PMID: 27944967.
    Citations:    
  75. Koo DJ, Jackman D, Chaudry IH, Wang P. Adrenal insufficiency during the late stage of polymicrobial sepsis. Crit Care Med. 2001 Mar; 29(3):618-22. PMID: 11373430.
    Citations: 13     Fields:    Translation:Animals
  76. Koo DJ, Zhou M, Jackman D, Cioffi WG, Bland KI, Chaudry IH, Wang P. Is gut the major source of proinflammatory cytokine release during polymicrobial sepsis? Biochim Biophys Acta. 1999 Aug 30; 1454(3):289-95. PMID: 10452963.
    Citations: 3     Fields:    Translation:AnimalsCells
  77. Jackman DM, Pham T, Noel JJ, Waddleton DM, Dhoot GK, Heeley DH. Heterogeneity of Atlantic salmon troponin-I. Biochim Biophys Acta. 1998 Sep 08; 1387(1-2):478-84. PMID: 9748666.
    Citations: 2     Fields:    Translation:AnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Jackman's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (227)
Explore
_
Co-Authors (64)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.